Esperion Therapeutics Inc. (NASDAQ:ESPR) finished Thursday with an addition of $0.09 to close at $1.68, an upside of 5.66 percent. An average of 3,545,900 shares of common stock have been traded in the last five days. There was a gain of $0.0400 in the past week, and it reached a new high 11 times over the past 12 months. The last 20 days have seen an average of 3,021,330 shares traded, while the 50-day average volume stands at 2,999,022.
ESPR stock has increased by 1.20% in the last month. The company shares reached their 1-month lowest point of $1.3550 on 07/27/23. With the stock rallying to its 52-week high on 01/10/23, shares of the company touched a low of $1.12 and a high of $8.87 in 52 weeks. It has reached a new high 4 times so far this year and lost -73.03% or -$4.5500 in price. In spite of this, the price is down -81.06% from the 52-week high.
Insider Transactions
ESPR stock investors should be aware that Esperion Therapeutics Inc. (ESPR) stock had its last reported insider trading activity 23 days ago on Jul 19. In this transaction, the insider spent $168. Chief Commercial Officer, Warren Eric, disposed of 603 shares at a price of $1.48 on Jun 21. The insider now owns more than $894 worth of shares. Prior to that, Chief Commercial Officer Warren Eric went on to Sale 219 shares at $1.62 each on May 17. An amount of $356 was transacted.
Valuation Metrics
Esperion Therapeutics Inc. (ESPR) stock’s beta is 0.13. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.06.
Financial Health
The quick ratio of Esperion Therapeutics Inc. for the three months ended June 29 was 1.70, and the current ratio was 2.20, indicating that the company is able to meet its debt obligations. Esperion Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -237.17%. Its gross profit as reported stood at $48.51 million compared to revenue of $75.47 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Esperion Therapeutics Inc.’s return on assets was -84.90%.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$49.94 million in the quarter, while revenues of -$61.72 million were shrunk -32.8%. The analyst consensus anticipated Esperion Therapeutics Inc.’s latest quarter earnings to come in at -$0.61 per share, but it turned out to be -$0.46, a 24.60% surprise. For the quarter, EBITDA amounted to -$36.66 million. Shareholders own equity worth $106.99 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Esperion Therapeutics Inc. (ESPR) price momentum. RSI 9-day as of the close on 10 August was 59.55%, suggesting the stock is Neutral, with historical volatility in this time frame at 99.69%.
As of today, ESPR’s price is $1.6220 +2.44% or $0.0400 from its 5-day moving average. ESPR is currently trading +11.26% higher than its 20-day SMA and +8.39% higher than its 100-day SMA. However, the stock’s current price level is +20.00% above the SMA50 and -78.35% below the SMA200.
The stochastic %K and %D were 43.31% and 40.86%, respectively, and the average true range (ATR) was 0.1591. With the 14-day stochastic at 51.18% and the average true range at 0.1509, the RSI (14) stands at 57.66%. The stock has reached -0.0144 on the 9-day MACD Oscillator while the 14-day reading was at 0.0550.
Analyst Ratings
Northland Capital upgraded Esperion Therapeutics Inc. (NASDAQ: ESPR) to a a Market perform rating in its most recent analyst report. Previously, the stock was rated as an Under perform. The consensus rating for Esperion Therapeutics Inc. (ESPR) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ESPR, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is ESPR’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $22.00, with a median target of $9.00. Taking a look at these predictions, the average price target given by analysts for Esperion Therapeutics Inc. (ESPR) stock is $10.28.
